Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia

BackgroundThe aims of this study were to describe outcome with respect to persistent psychotic symptoms, relapse of positive symptoms, hospital admissions, and application of treatment by coercion among patients with recent onset schizophrenia being adherent and non-adherent to anti-psychotic medication.Materials and methodsThe study included 50 patients with recent onset schizophrenia, schizoaffective or schizophreniform disorders. The patients were clinically stable at study entry and had less than 2 years duration of psychotic symptoms. Good adherence to antipsychotic medication was defined as less than one month without medication. Outcomes for poor and good adherence were compared over a 24-month follow-up period.ResultsThe Odds Ratio (OR) of having a psychotic relapse was 10.27 and the OR of being admitted to hospital was 4.00 among non-adherent patients. Use of depot-antipsychotics were associated with relapses (OR = 6.44).ConclusionNon-adherence was associated with relapse, hospital admission and having persistent psychotic symptoms. Interventions to increase adherence are needed.Trial registrationCurrent Controlled Trials NCT00184509. Key words: Adherence, schizophrenia, antipsychotic medication, admittances, relapse.

[1]  G. Morken,et al.  Effects of integrated treatment on antipsychotic medication adherence in a randomized trial in recent-onset schizophrenia. , 2007, The Journal of clinical psychiatry.

[2]  U. Malm,et al.  The clinical strategies implementation scale to measure implementation of treatment in mental health services. , 2005, Psychiatric services.

[3]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[4]  G. Krarup,et al.  Improving 1-year outcome in first-episode psychosis , 2005, British Journal of Psychiatry.

[5]  A. Malla,et al.  EEG abnormalities and two year outcome in first episode psychosis , 2005 .

[6]  G. Dunn,et al.  The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis , 2004, BMJ : British Medical Journal.

[7]  R. Bentall,et al.  Cognitive therapy for the prevention of psychosis in people at ultra-high risk , 2004, British Journal of Psychiatry.

[8]  U. Malm,et al.  Implementation of evidence-based treatment for schizophrenic disorders: two-year outcome of an international field trial of optimal treatment. , 2004, World psychiatry : official journal of the World Psychiatric Association.

[9]  R. Rosenheck,et al.  An exploratory analysis of correlates of recovery. , 2004, Psychiatric services.

[10]  Christian R. Dolder,et al.  Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. , 2004, The American journal of psychiatry.

[11]  R. Liberman,et al.  Integrating treatment with rehabilitation for persons with major mental illnesses. , 2003, Psychiatric services.

[12]  Robert E Drake,et al.  Implementing Evidence-Based Practices for People with Severe Mental Illness , 2003, Behavior modification.

[13]  I. Falloon.  Family interventions for mental disorders: efficacy and effectiveness. , 2003, World psychiatry : official journal of the World Psychiatric Association.

[14]  I. Wieselgren,et al.  One‐year outcome in first episode psychosis patients in the Swedish Parachute project , 2002, Acta psychiatrica Scandinavica.

[15]  J. Addington,et al.  Medication adherence of individuals with a first episode of psychosis , 2002, Acta psychiatrica Scandinavica.

[16]  Hok Pan Yuen,et al.  Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. , 2002, Archives of general psychiatry.

[17]  Laurel,et al.  Pharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission , 2002, Medical care.

[18]  P Bebbington,et al.  Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy , 2002, Psychological Medicine.

[19]  R. Taylor,et al.  NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (NICE) , 2002, International Journal of Technology Assessment in Health Care.

[20]  A. Malla,et al.  Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. , 2002, Psychiatric services.

[21]  Rose M. Allinder,et al.  Translating Research Into Practice , 2001 .

[22]  D. Linszen,et al.  Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications , 2001, Schizophrenia Research.

[23]  J. Cullberg,et al.  First-episode non-affective psychosis in a total urban population: a 5-year follow-up , 2001, Social Psychiatry and Psychiatric Epidemiology.

[24]  S. Francey,et al.  Cognitively oriented psychotherapy for early psychosis (COPE): a 1-year follow-up. , 2001, The British journal of clinical psychology.

[25]  E. O'callaghan,et al.  Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia. , 2001, Psychiatric services.

[26]  S. Keith,et al.  The psychosocial treatment of schizophrenia: an update. , 2001, The American journal of psychiatry.

[27]  E. Susser,et al.  Evidence-based psychotherapeutic interventions in the community care of schizophrenia , 2001, British Journal of Psychiatry.

[28]  K. Nuechterlein,et al.  Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale , 2000, Psychiatry Research.

[29]  Alexander L. Miller,et al.  Evidence-based treatment of schizophrenia , 2000, The Psychiatric clinics of North America.

[30]  I. Falloon.  Rehab Rounds : Optimal Treatment for Psychosis in an International Multisite Demonstration Project , 1999 .

[31]  R. Drake,et al.  A pilot study evaluating the effectiveness of individual inpatient cognitive-behavioural therapy in early psychosis , 1999, Social Psychiatry and Psychiatric Epidemiology.

[32]  J. Lieberman,et al.  Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. , 1999, Archives of general psychiatry.

[33]  J. Coverdale,et al.  Optimal Treatment Strategies to Enhance Recovery from Schizophrenia , 1998, The Australian and New Zealand journal of psychiatry.

[34]  José L. Ayuso-Gutiérrez,et al.  Factors influencing relapse in the long-term course of schizophrenia , 1997, Schizophrenia Research.

[35]  D. Linszen,et al.  Treatment, expressed emotion and relapse in recent onset schizophrenic disorders , 1996, Psychological Medicine.

[36]  M. Sullivan,et al.  Drs. Sullivan and Youngner Reply , 1995 .

[37]  J L Cavanaugh,et al.  Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. , 1995, The American journal of psychiatry.

[38]  H. Blume,et al.  Presentation of the intrasubject coefficient of variation for sample size planning in bioequivalence studies. , 1994, International journal of clinical pharmacology and therapeutics.

[39]  Robert Paul Liberman,et al.  Training and quality assurance with the Brief Psychiatric Rating Scale: "The drift busters." , 1993 .

[40]  Z. Mahmood,et al.  The Scottish First Episode Schizophrenia Study , 1992, British Journal of Psychiatry.

[41]  I. Falloon,et al.  Early intervention for first episodes of schizophrenia: a preliminary exploration. , 1992, Psychiatry.

[42]  D. Pickar,et al.  National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. , 1991, Archives of general psychiatry.

[43]  N. Tarrier,et al.  The Community Management of Schizophrenia , 1988, British Journal of Psychiatry.

[44]  T. Crow,et al.  II. A Randomised Controlled Trial of Prophylactic Neuroleptic Treatment , 1986, British Journal of Psychiatry.

[45]  H. Moss,et al.  Family management in the prevention of exacerbations of schizophrenia: a controlled study. , 1982, The New England journal of medicine.

[46]  L. Kirk,et al.  [Treatment of schizophrenia]. , 1971, Ugeskrift for laeger.

[47]  C. G. Restrepo.  Reseña de "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia" de Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO , 2006 .

[48]  D. Charney,et al.  Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative. , 2004, The American journal of psychiatry.

[49]  Alexander L. Miller,et al.  Practice guideline for the treatment of patients with schizophrenia, second edition. , 2004, The American journal of psychiatry.

[50]  R. Hu.  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) , 2003 .

[51]  E. O'callaghan,et al.  Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia. , 2001, Psychiatric services.

[52]  I. Falloon.  Optimal treatment for psychosis in an international multisite demonstration project. Optimal Treatment Project Collaborators. , 1999, Psychiatric services.

[53]  R Giel,et al.  Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. , 1998, Schizophrenia bulletin.

[54]  D M Steinwachs,et al.  Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. , 1998, Schizophrenia bulletin.

[55]  W S Fenton,et al.  Determinants of medication compliance in schizophrenia: empirical and clinical findings. , 1997, Schizophrenia bulletin.

[56]  Julie Kreyenbuhl,et al.  Practice guideline for the treatment of patients with schizophrenia , 1997 .

[57]  C. Mihalopoulos,et al.  EPPIC: an evolving system of early detection and optimal management. , 1996, Schizophrenia bulletin.

[58]  H. Morgenstern,et al.  Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. , 1995, The American journal of psychiatry.

[59]  P. Weiden,et al.  Rating of medication influences (ROMI) scale in schizophrenia. , 1994, Schizophrenia bulletin.

[60]  I. Falloon,et al.  Integrated mental health care , 1993 .

[61]  S. Marder,et al.  Psychopharmacologic treatment of schizophrenia. , 1993, Schizophrenia bulletin.

[62]  K. Nuechterlein,et al.  Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress. , 1992, Schizophrenia bulletin.

[63]  R J Wyatt,et al.  Neuroleptics and the natural course of schizophrenia. , 1991, Schizophrenia bulletin.

[64]  Werner Kissling.  The current unsatisfactory state of relapse prevention in schizophrenic psychoses--suggestions for improvement. , 1991, Clinical neuropharmacology.

[65]  N. Schooler.  Maintenance Medication for Schizophrenia: Strategies for Dose Reduction , 1991 .

[66]  N. Smeeton,et al.  The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. , 1989, Psychological medicine. Monograph supplement.